Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 17/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21588419 | 0.71 | HTR6 (0.56) | HTR6 | |
| SCHEMBL21588271 | 0.66 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL21162350 | 0.64 | CYP3A4 (0.48) | — | |
| SCHEMBL25684834 | 0.64 | PARP1 (0.42) | HTR6 | |
| SCHEMBL26880294 | 0.61 | SIGMAR1 (0.49) | SIGMAR1HTR6 | |
| SCHEMBL26880314 | 0.61 | SIGMAR1 (0.49) | SIGMAR1HTR6 | |
| SCHEMBL7406069 | 0.61 | SIGMAR1 (1.00) | SIGMAR1HTR6 | |
| SCHEMBL11445321 | 0.59 | PER2 (0.41) | — | |
| SCHEMBL26880323 | 0.55 | CHRNB2 (0.43) | SIGMAR1HTR6 | |
| SCHEMBL21162344 | 0.54 | PARP1 (0.42) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | SIGMAR1 3595/4885HTR6 2414/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | SIGMAR1 3877/4885HTR6 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.